Clinical Trials for Cancer Type: Myeloid and Monocytic Leukemia

10 Open Trials. Phone:(877.827.8839)
Protocol No. Title Status
UCI-14-89 [BIOREPOSITORY] Hematologic Malignancies Biorepository for human research Open
UCI-16-01 Pathway Analyses for Individualized Network Therapeutics for Cancer (PAINT Cancer) Open
UCI-16-100 A Phase II/III Multicenter, Open-label, Three-Arm, Two-Stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy Open
UCI-16-95 A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study of a Non-Covalent, Reversible Bruton's Tyrosine Kinase Inhibitor, SNS 062, in Patients With B-Lymphoid Malignancies Open
UCI-17-02 A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABBV-744 in Subjects with Metastatic Castrate Resistant Prostate Cancer (CRPC) and Relapsed/Refractory Acute Myeloid Leukemia (AML) Open
UCI-17-105 The Value of Hair in Chemotherapy Open
UCI-17-114 A Randomized (1:1), Double-Blind, Multi-Center, Placebo Controlled Study Evaluating Intensive Chemotherapy With or Without Glasdegib (PF-04449913) or Azacitidine (AZA) With or Without Glasdegib in Patients with Previously Untreated Acute Myeloid Leukemia Open
UCI-17-19 A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Ascending Doses of AZD5991 in Subjects with Relapsed or Refractory Haematologic Malignancies Open
UCI-17-31 An Open-Label Phase II Study of Itacitinib (INCB039110) in Combination with Low Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects with Myelofibrosis Open
UCI-18-09 A Phase 1b Study of Venetoclax and Alvocidib in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) Open